Xencor Q4 2022 Earnings Report
Key Takeaways
Xencor reported a net loss of $12.0 million for the fourth quarter of 2022, compared to a net income of $73.1 million for the same period in 2021. Total revenue for the fourth quarter was $21.6 million, compared to $154.0 million for the same period in 2021. The company's cash, cash equivalents, receivables, and marketable debt securities totaled $613.5 million as of December 31, 2022.
Advanced internal portfolio of XmAb drug candidates.
Initiated Phase 1 studies for two novel T-cell engagers, XmAb819 and XmAb808.
Expect to further expand wholly owned portfolio by initiating a Phase 1 study for XmAb662.
Anticipate submitting an IND for XmAb541.
Xencor
Xencor
Forward Guidance
Xencor expects to end 2023 with between $425 million and $475 million in cash, cash equivalents, receivables and marketable debt securities, and to have cash to fund research and development programs and operations through the end of 2025.